1 Multi-omics profiling of DNA methylation and gene expression alterations in 2 human cocaine use disorder

Eric Zillich¹, Hanna Belschner¹, Diana Avetyan¹, Diego Andrade-Brito^{1,2,3}, José Jaime
Martínez-Magaña^{2,3}, Josef Frank¹, Naguib Mechawar^{4,5}, Gustavo Turecki^{4,5}, Judit CabanaDomínguez⁶, Noèlia Fernàndez-Castillo⁷, Bru Cormand⁷, Janitza L. Montalvo-Ortiz^{2,3,8}, Markus
M. Nöthen⁹, Anita C. Hansson¹⁰, Marcella Rietschel¹, Rainer Spanagel^{10,12}, Stephanie H.
Witt^{1,11,12*}, Lea Zillich^{1,12,13*}

- ¹ Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical
 9 Faculty Mannheim, Heidelberg University, Mannheim, Germany
- 10 ² Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
- 12 ³ VA CT Healthcare Center, West Haven, CT, USA
- ⁴ McGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, QC, Canada
- ⁵ Department of Psychiatry, McGill University, Montreal, QC, Canada
- ⁶ Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research
- 16 Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona,
- 17 Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain.

⁷ Department de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona,
and Institut de Biomedicina de la Universitat de Barcelona (IBUB); Barcelona, Catalonia, Spain; Centro
de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III
(ISCIII); Madrid, Spain; Institut de Recerca Sant Joan de Déu (IR-SJD), Esplugues de Llobregat,
Barcelona, Catalonia, Spain

- ⁸ US Department of Veterans Affairs National Center of Posttraumatic Stress Disorder, Clinical
 Neurosciences Division, West Haven, CT, USA
- ⁹ Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn,
 Bonn, Germany
- ¹⁰ Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim,
 Heidelberg University, Mannheim, Germany
- ¹¹ Center for Innovative Psychiatric and Psychotherapeutic Research, Biobank, Central Institute of
 Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- 31 ¹² German Center for Mental Health (DZPG), partner site Mannheim/Heidelberg/Ulm
- 32 ¹³ HITBR Hector Institute for Translational Brain Research gGmbH, Mannheim, Germany
- 33
- 34 *shared last-authorship
- 35 corresponding author: stephanie.witt@zi-mannheim.de
- 36
- 37

38 Abstract

39 Structural and functional changes of the brain are assumed to contribute to excessive cocaine intake, 40 craving, and relapse in cocaine use disorder (CUD). Epigenetic and transcriptional changes were 41 hypothesized as a molecular basis for CUD-associated brain alterations. Here we performed a multi-42 omics study of CUD by integrating epigenome-wide methylomic (N=42) and transcriptomic (N=25) data 43 from the same individuals using postmortem brain tissue of Brodmann Area 9 (BA9). Of the N=1,057 44 differentially expressed genes (p<0.05), one gene, ZFAND2A, was significantly upregulated in CUD at 45 transcriptome-wide significance (q<0.05). Differential alternative splicing (AS) analysis revealed N=98 46 alternatively spliced transcripts enriched in axon and dendrite extension pathways. Strong convergent 47 overlap in CUD-associated expression deregulation was found between our BA9 cohort and 48 independent replication datasets. Epigenomic, transcriptomic, and AS changes in BA9 converged at two 49 genes, ZBTB4 and INPP5E. In pathway analyses, synaptic signaling, neuron morphogenesis, and fatty 50 acid metabolism emerged as the most prominently deregulated biological processes. Drug repositioning 51 analysis revealed glucocorticoid receptor targeting drugs as most potent in reversing the CUD 52 expression profile. Our study highlights the value of multi-omics approaches for an in-depth molecular 53 characterization and provides insights into the relationship between CUD-associated epigenomic and 54 transcriptomic signatures in the human prefrontal cortex.

55

56 Introduction

57 Cocaine use disorder (CUD) is a globally prevalent substance use disorder (SUD) with around 4.2 million 58 people worldwide being diagnosed with CUD¹. Individuals suffering from CUD present with compulsive 59 cocaine use patterns, strong cocaine craving, and high rates of relapse even after prolonged time of 60 abstinence². Currently, there is no FDA-approved pharmacotherapy for CUD and treatment is mainly 61 focused on symptom reduction³. Neurobiological alterations in the brain are assumed to contribute to 62 the observed clinical symptoms in CUD⁴. This is supported by neuroimaging studies that have shown 63 profound structural and functional alterations in the brain in individuals with CUD^{5,6}. In addition to striatal 64 brain regions involved in reward processing⁷, frontal cortical areas that are neuroanatomically connected 65 with limbic structures, are implicated in addiction due to their importance for inhibitory control^{5,6,8}.

66

67 Dynamic changes in epigenetics and gene expression were hypothesized as a molecular basis of CUD-68 associated brain changes^{9,10}. So far, the majority of studies investigating brain tissue focused on rodent 69 models of cocaine addiction, identifying specific genomic loci to be differentially methylated in brain 70 regions such as the prefrontal cortex (PFC)¹¹ and nucleus accumbens (NAc)¹². Gene expression levels 71 are tightly regulated by epigenetic mechanisms and DNA methylation (DNAm) changes especially in 72 gene promoter regions were shown to alter transcript abundance¹³. In line with this, differential gene 73 expression in rodent models of cocaine addiction was reported in different brain regions where 74 transcription factors of the immediate early gene (IEG) family such as Egr1, Nr4a1, and Fos were found 75 to be differentially expressed¹⁴⁻¹⁷. At the transcriptome-wide scale, differentially expressed genes were 76 consistently enriched in biological processes related to neurotransmission and ion channel activity, but 77 also metabolic alterations related to lipid metabolism and ATP homeostasis were found¹⁴.

78

79 Few studies have been performed investigating genome-wide DNAm or transcriptomic changes in CUD 80 in human postmortem brain tissue. Two epigenome-wide studies using reduced representation bisulfite 81 sequencing (RRBS) in a cohort of N=25 individuals with CUD and N=25 control individuals identified 82 N=145 and N=173 CUD-associated differentially methylated regions (DMRs) in the nucleus accumbens 83 (NAc)¹⁸ and in the caudate nucleus (CN)¹⁹, respectively. Investigating the same brain regions in a 84 different cohort (N=25 CUD cases, N=20 controls), another study characterized transcriptome-wide 85 gene expression changes and reported on the upregulation of synaptic transmembrane transporter 86 genes while immune processes were downregulated²⁰. The largest study in the human PFC 87 investigating CUD-associated transcriptomic changes (N=19 CUD, N=17 controls) identified N=883 88 nominally significant (p<0.05) differentially expressed genes (DEGs) in neuronal nuclei from the 89 Brodmann Area 46 subregion²¹. CUD-associated co-expression networks were enriched for GTPase 90 signaling and neurotransmitter secretion. Regarding epigenomic alterations in the PFC, we were 91 previously able to identify 20 CUD-associated DMRs in Brodmann Area 9, a subregion of the PFC, and 92 further detected that co-methylation networks in CUD were enriched for synaptic signaling processes²². 93 Although epigenetics represents an important regulatory mechanism for transcription, the co-regulation 94 of DNAm and gene expression in the same brain samples has not yet been investigated in CUD, limiting 95 the comparability of results between epigenetic and gene expression studies.

96

97 In addition to epigenetics and transcription, alterations of alternative splicing might contribute to the 98 neurobiological changes in the CUD brain, as shown in other SUDs. Previous studies using postmortem 99 human brain tissue from individuals with alcohol use disorder (AUD)²³⁻²⁵ and opioid use disorder (OUD)²⁶ 100 detected differential alternative splicing in transcripts of genes implicated in neuropsychiatric disorders, 101 such as BIN1, FLOT1, and ELOVL7 suggesting RNA splicing alterations to be a further molecular 102 mechanism in the neurobiology of SUDs. While a recent study using a cocaine self-administration model 103 in mice showed widespread changes in alternative splicing in multiple brain regions²⁷, no systematic 104 evaluation of splicing alterations in human CUD was performed so far.

105

106 In the present study, we aimed to characterize the molecular underpinings of CUD in the human 107 prefrontal cortex by applying a multi-omics analysis approach. We investigated differentially expressed 108 genes in postmortem brain tissue from deceased CUD cases compared to well-matched controls and 109 integrated them with the results of our epigenome-wide DNAm analysis¹⁸ from the same individuals of 110 the BA9 subregion of the human PFC. Further, we characterized differential alternative splicing in BA9. 111 We then performed replication analysis of CUD-associated DEGs in two other independent RNA-seq 112 datasets of human dIPFC. Gene expression data, including alternative splicing results, and DNA 113 methylation data were then integrated and put into a biological context. Finally, we addressed the urgent 114 need for novel therapeutic approaches, by performing a drug repositioning analysis based on the CUD-115 associated transcriptional profile in BA9.

116

117 Collectively, our multi-omics study design represents an integrated analysis of DNAm and gene 118 expression data together with alternative transcript splicing that highlights the role of synaptic and 119 metabolic alterations in CUD and the glucocorticoid receptor as a pharmacological candidate target.

120

121 Results

Individuals with and without CUD do not differ in sociodemographic characteristics and cell type composition

We first assessed the phenotypic similarities between CUD cases and controls. No significant differences were observed regarding the pH value of the brain, postmortem interval (PMI), RNA integrity number (RIN), and occurrence of comorbid depressive and alcohol use disorders (Supplementary Table S1). We further investigated the variance partition of potential covariates in the RNA-seq dataset

128 (Supplementary Fig. S1a) and found age, PMI, brain pH, and RIN to be associated with gene expression 129 levels, and hence included them as covariates in further analyses. To explore whether major cell type 130 composition could affect analysis results, we performed a cell type deconvolution analysis using 131 CIBERSORT based on human PFC major cell type marker gene signatures (Supplementary Fig. S1b, 132 Supplementary Table S2a). No significant differences in the distribution of major cell types such as 133 astrocytes, oligodentrocytes, microglia, neurons and others were detected between samples from 134 individuals with and without CUD as all 95% high-density intervals from the Bayesian estimation 135 contained 0 (Supplementary Table S2b).

136

137 Transcriptome-wide differential gene expression patterns in CUD are related to synaptic 138 signaling, ion transport, and inflammatory processes

139 The transcriptome-wide analysis of differential expression in BA9 revealed a total of N=1,057 DEGs 140 associated with CUD (p<0.05). Of these, N=378 were upregulated and N=679 were downregulated (Fig. 141 1a, Supplementary Table S3). After adjustment for multiple testing, ZFAND2A (Zinc Finger AN1-Type 142 Containing 2A, log2FC=0.43, p=1.98e-06, q=0.04), remained significantly upregulated in individuals with 143 CUD (5% FDR). We observed a genomic inflation factor of λ =1.29 (Supplementary Fig. S1c) and results 144 were stable in a sensitivity analysis without individuals with AUD or MDD (Supplementary Fig. S1d). To 145 evaluate whether BA9 DEGs are significantly enriched within cell-type specific genes of the human PFC, 146 we performed an overlap analysis, using the same set of major brain cell type marker genes as in the 147 cell type composition analysis. Upregulated DEGs were significantly enriched for neuron marker genes 148 exclusively, whereas downregulated DEGs were significantly enriched in markers of non-neuronal cell 149 types such as astrocytes, endothelial cells, and oligodendrocytes (Fig. 1b).

150

151 Next, we were interested in the biological functions related to the identified CUD-associated DEGs. After 152 adjusting for multiple testing, we detected N=276 statistically significant GO terms for positive GSEA 153 normalized enrichment scores (NES, Supplementary Table S4) and N=782 significant GO terms for 154 negative NES (Supplementary Table S5). Among significantly enriched pathways, the largest positive 155 NES was detected for "vesicle-mediated transport in synapse" (NES=2.63, g=5.31e-15), whereas 156 "superoxide metabolic process" (NES=-2.43, g=2.08e-06) was the top finding with negative NES. To 157 identify functional modules of pathways consisting of multiple GO terms related to similar biological 158 functions, we created an enrichment map (emap) visualization based on the significant findings from GSEA. For GO terms with negative NES, we detected one large cluster related to inflammatory and immune signaling and several smaller clusters consisting of pathways involved in angiogenesis, extracellular matrix (ECM) organization, and gliogenesis (Fig. 1c). Two major clusters emerged for pathways with positive NES. The first was related to neurotransmission and synaptic signaling whereas the second cluster consisted of GO terms involved in transmembrane transporter activity (Fig. 1d).



165 Fig. 1 – Differential expression analysis in CUD suggests synaptic signaling and immunological alterations in Brodmann

166 Area 9

164

167 a Volcano plot of the differential expression (DE) analysis showing the N=378 upregulated (red) and N=679 downregulated genes

168 (blue) at nominal significance (p<0.05). Solid black line indicates nominal significance (p<0.05), dashed gray line indicates

transcriptome-wide significance (FDR q<0.05). **b** Results of the overlap analysis for upregulated (up) and downregulated (down)

DEGs among cell-type specific marker genes. Green color depicts the odds ratio (OR) of overlap, p-values inside the panels indicates significance of overlap based on Fisher-Test. Gene-set enrichment analysis (GSEA) was performed for the DEGs in BA9 ranked by the Wald test statistic from DESeq2. Statistically significant results (q<0.05) from GSEA separated by **c** negative and **d** positive normalized enrichment scores (NES) are shown in an enrichment map visualization. N.S. = not significant, OPC = oligodendrocyte progenitor cell.

175

176 Network analysis highlights fatty-acid metabolism and morphogenesis processes in CUD

177 We next performed weighted gene co-expression network analysis (WGCNA) to investigate gene co-178 expression patterns in CUD and detected a total of N=27 co-expression modules (Supplementary Fig. 179 S2a+2b). Co-expression module yellow was significantly correlated with CUD (r=-0.47, p=0.02) while 180 no significant association with other known covariates was observed (Supplementary Fig. S2a). Module 181 yellow consisted of N=2,517 genes and module membership was highly correlated with gene 182 significance for CUD (r=0.61, p<1e-200, Supplementary Fig. S2c, Table S6). GO enrichment analysis 183 for module yellow genes revealed N=519 statistically significant GO terms after multiple testing 184 correction (Supplementary Table S7). Strongest associations were detected for "small molecule 185 catabolic process" (q=2.22e-11), and more specifically, "carboxylic acid catabolic process" (q=1.59e-09, 186 Supplementary Fig. S2d). After clustering the significant terms, a prominent GO term cluster related to 187 fatty acid metabolism was detected, while another cluster was related to organ developmental and 188 morphogenesis processes. To further characterize WGCNA expression module yellow, we generated a 189 protein-protein interaction (PPI) network based on module hub genes and identified APOE (N=9 edges), 190 ERBB2 (N=8 edges), ALDH7A1 (N=7 edges), PPARA (N=7 edges), and TLR4 (N=7 edges) as the most 191 strongly connected nodes in the PPI network (Supplementary Fig. S3, Supplementary Table S6).

192

Genes with alternative splicing events in CUD are involved in cell junction formation and the morphogenesis of axons and dendrites

To investigate alternative splicing in CUD and its potential relevance for contributing to altered neurobiological functions in the brain, we performed a differential alternative splicing analysis using LeafCutter²⁸. After multiple testing correction, we identified a total of N=108 differentially spliced intron clusters in BA9 (FDR<0.05, Fig. 2a, Supplementary Tables S8-S10). These clusters were distributed among N=98 genes that we further denote as alternatively spliced (AS) genes. One of the top findings in our AS analysis of CUD was *BIN1* (*Bridging Integrator 1*, q=7.8e-04, Fig. 2b) previously identified as a conserved AS genes in other substance use disorders. We next investigated the biological pathways 202 enriched for alternative splicing events based on our list of AS genes. Statistically significant enrichment 203 after multiple testing correction was detected for N=15 GO terms (Supplementary Table S10). Strongest 204 enrichment was found for GO terms "cell junction assembly" and "neuron projection extension" (both 205 q=3.62e-03). In the emap visualization of enriched GO terms with a more lenient threshold of 25% FDR 206 (q<0.25), we detected a well-connected cluster containing GO terms related to cellular growth and cell-207 cell junction development, while also more brain-specific processes such as myelination and the 208 extension of axons and dendrites were found (Fig. 2c). While differential alternative splicing itself 209 contributes to altered biological functions by inducing different abundances of transcript isoforms, this 210 effect might be potentiated by differential gene expression. We thus investigated the overlap of AS and 211 DEGs in CUD and identified 8 genes that were differentially spliced and differentially expressed in BA9: 212 ITPKB, CPLX1, HLA-F, INPP5E, GALNT8, IGFBP6, ZBTB4, and BCAT2 (Fig. 2d).

213





214

215 Fig. 2 – Differential alternatively spliced genes in CUD are related to neuron morphogenetic processes

216 a Volcano plot of the differential alternative splicing (AS) results in Brodmann Area 9 (BA9). Statistically significant intron clusters 217 (N=108) identified by LeafCutter (q<0.05) were annotated by gene name while dots represent individual introns of an intron cluster. 218 Introns highlighted in red (dPSI>0) are more abundant in CUD while introns highlighted in blue (dPSI<0) are less abundant in 219 CUD. b Results of the differential AS analysis at the cluster and gene level for one of the top findings, an intron cluster (clu_14172_-220) in the Bridging Integrator 1 (BIN1) gene. Upper panel: visualization of BIN1 exons and introns with percent spliced in (PSI) 221 measures related to the significant cluster clu_14172_-. The table indicates delta percent spliced in (dPSI) values from the CUD 222 vs. Ctrl comparison. Lower panel: gene-level summary of all intron clusters detected in BIN1. FDR q-values are shown below 223 cluster names. c GO enrichment analysis for the N=98 AS genes harboring differentially statistically significant (q<0.05) intron 224 clusters in CUD. d Overlap of findings from differential expression (DE) analysis (N=1057 DEGs at p<0.05) and differential AS 225 analysis.

226 Replication analysis in independent cohorts reveals *FKBP4* and *HSPA6* as conserved DEGs in

227 CUD

228 To evaluate the potential replication of CUD-associated DEGs in other RNA-seq datasets of human 229 PFC, we performed an overlap analysis of nominally significant DEGs (p<0.05) across studies. CUD-230 associated differential expression testing was performed in two independent replication datasets, the 231 first originating from BA9 (BA9 replication, bulk RNA-seq) and the second from BA46 (BA46 replication, 232 neuron-specific RNA-seq). Two genes, HSPA6 and FKBP4, were shared upregulated DEGs at nominal 233 significance and showed comparable effect sizes (log2FC) in CUD across all three PFC datasets (Fig. 234 3a+c). As HSPA6 is a spliceosome-associated gene with conserved differential expression across 235 datasets, we performed a look-up of genes related to the KEGG Spliceosome pathway (hsa03040) in 236 DE results from our discovery cohort (Fig. 3b). Here, we aimed to address the hypothesis of 237 spliceosomal differential gene expression as a potential mechanism for splicing alterations in CUD²⁹. 238 HSPA6 was the spliceosome-associated gene showing strongest CUD-associated expression changes 239 in BA9 (log2FC=2.59, p=0.002). We detected six additional spliceosome-associated genes that were 240 among nominally significant DEGs: HSPA1A (log2FC=0.71, p=0.034), CRNKL1 (log2FC=-0.19, 241 p=0.011), LSM6 (log2FC=-0.24, p=0.014), SRSF4 (log2FC=-0.14, p=0.022), SNRPG (log2FC=-0.20, 242 p=0.037), and TRA2A (log2FC=-0.14, p=0.036).

243

Using rank-rank hypergeometric overlap (RRHO) visualization for a more unbiased evaluation of convergent and divergent gene expression patterns across studies, we found strong convergent overlap between the BA9 discovery and BA9 replication datasets indicating similar patterns of CUD-associated expression deregulation (Fig. 3d). In the comparison with neuron-specific expression data from BA46, we found prominent divergent gene expression patterns between datasets, while convergent expression patterns were enriched in the shared upregulated genes across studies (Fig. 3e).

a **DEG overlap – CUD vs. Ctrl** (nominal p<0.05)





BA46 replication (Ribeiro et al., 2017)

С		(
		BA9 discovery (N=25)		BA9 replication (N=21)		BA46 replication (N=36)	
	Gene (RNA)	log2FC	p-value	log2FC	p-value	log2FC	p-value
	HSPA6	2.59	0.002	2.45	0.005	3.90	0.02
	FKBP4	0.21	0.04	0.30	0.02	0.38	0.05





a Overlap of nominally significant (p<0.05) differentially expressed genes across datasets reveals two shared DEGs, HSPA6 and FKBP4. The replication datasets were based on N=21 BA9 samples from the National PTSD Brain Bank (NPBB) and neuronalspecific transcriptomic data of N=36 BA46 samples available under GEO accession number GSE99349 (BA46 replication). **b** HSPA6 is the strongest spliceosome-associated DEG in BA9. **c** Results of the look-up analysis for shared DEGs HSPA6 and FKBP4 - log2-fold change and p-value: association p-value from the DESeq2-based differential expression results. Significant associations are highlighted in bold. Rank-rank hypergeometric overlap (RRHO) visualization for **d** the BA9 replication dataset and **e** the neuronal-specific BA46 dataset indicating convergent and divergent expression patterns across studies using full

- 258 differential expression statistics as the input datasets. Color scale represents $-\log_{10}(p)$ of the hypergeometric testing procedure in
- 259 RRHO. Convergent expression across datasets: up-up and down-down, divergent: up-down and down-up.
- 260

261 Drug repositioning analysis highlights glucocorticoid receptor targeting drugs to reverse the

262 CUD gene expression profile

263 To evaluate the potential use of small molecule drugs to revert the gene expression pattern of CUD, we 264 performed drug repositioning analysis based on the L1000 assay as implemented in CMap 265 (Supplementary Fig. S4a), using the top 150 up- and downregulated genes as input (Supplementary 266 Table S11). Among the results with negative normalized connectivity score (NCS), i.e. perturbagens 267 that revert the DE profile in CUD, the most significant finding for small molecule drugs after multiple 268 testing correction was the glucocorticoid receptor agonist medrysone (NCS=-1.78, q=2.2e-16, 269 Supplementary Fig. S4b). Glucocorticoid receptor agonists were the only FDR-significant perturbagen 270 class overrepresented among CMap GSEA results (Supplementary Fig. S4c). When we further 271 investigated connectivity scores for all glucocorticoid receptor targeting drugs including agonists and 272 antagonists in CMap, we found exclusively significant negative connectivity scores (Supplementary Fig. 273 S4d) suggesting glucocorticoid receptor targeting molecules as potential pharmacological drugs to 274 revert the CUD expression changes in BA9. In line with this finding, the biological pathway "response to 275 glucocorticoid" (NES=-1.54, q=0.019, Supplementary Table S5) was among the FDR-significant 276 pathways with negative NES in the GSEA analysis of DEGs from BA9.

277

Findings of the integrated analysis of DNA methylation and gene expression data converge atthe gene and pathway levels

As DNA methylation data was available and previously analyzed for the same cohort in BA9, we next aimed to integrate findings from the epigenome-wide and transcriptome-wide studies on the gene-level, applied multi-omics factor analysis, and performed an integrative functional GO-term enrichment analysis across all –omics layers.

284

Gene-level integration of epigenomic, transcriptomic and splicing alterations highlights ZBTB4 and
 INPP5E in CUD

Of the overlapping genes between the differential methylation, expression, and alternative splicing analyses, two genes were consistently altered across all the investigated molecular views in BA9: ZBTB4 (Zinc Finger And BTB Domain Containing 4) and INPP5E (Inositol polyphosphate-5290 phosphatase E) (Fig. 4a, Supplementary Table S12). Both genes were characterized by a 291 hypomethylated CpG site and increased transcript levels in CUD (Fig. 4b). For ZBTB4, the strongest 292 association for a CpG site was found for cg03443505 (chr17:7387573, β =-0.84, p=1.01e-05). ZBTB4 293 was upregulated with a log2FC of 0.08 (p=0.015) and it contained the differentially spliced intron cluster 294 chr17:clu 10246 - (g=0.028). The strongest association for CpG differential methylation in the INPP5E 295 gene was found for cg18558462 (chr9:139334381, β =-0.93, p=8.55e-03). It was differentially expressed 296 with log2FC of 0.17 (p=0.025) and intron cluster chr9:clu 25078 - was differentially alternatively spliced 297 (q=0.015). In the replication datasets, we detected conserved transcript upregulation of ZBTB4 (BA9 298 replication, log2FC=0.12, pval=0.21; BA46, log2FC=0.12, pval=0.09) and INPP5E (BA9 replication, 299 log2FC=0.11, pval=0.47; BA46, log2FC=0.08, pval=0.49), however not statistically significant. To 300 deeper characterize the ZBTB4 and INPP5E gene loci in BA9 and specifically in the context of CUD, we 301 performed an integrative gene locus visualization approach by combining GWAS, EWAS, alternative 302 splicing, and RNA-seq results for CUD with ENCODE ChIP-seq reference data from human dorsolateral 303 prefrontal cortex. ChIP-seg data confirmed the presence of activating chromatin marks at promoter 304 (H3K4me4, H3K27ac) and gene body regions (H3K36me3) at ZBTB4 and INPP5E gene loci in the 305 human dIPFC. In addition, for ZBTB4, multiple nominally significant associations for SNPs and CpG 306 sites were detected that were most prominent within intronic and intergenic regions, while no SNP but 307 CUD-associated CpG sites were identified in the INPP5E gene locus (Fig. 4c). In line with this, when 308 we quantified the association of genetic variants with CUD at the gene level using a gene-based 309 association analysis in MAGMA, we detected stronger association for ZBTB4 with CUD (Z=1.74; p=0.04) 310 compared to *INPP5E* (Z=-1.14; p=0.87).



311

Fig. 4 - Convergence of DNA methylation, alternative splicing, and gene expression alterations in CUD at the *ZBTB4* and *INPP5E* gene loci

a Overlap of differential expression (DE), differential DNA methylation (DiffMeth), and differential alternative splicing analyses suggest two genes, *ZBTB4* and *INPP5E*, where alterations are consistently associated with CUD. **b** Relationship between DE and DiffMeth genes in Brodmann Area 9 based on log2FC (y-axis) from DE analysis and effect size β from linear regression in the EWAS of CUD (x-axis). For both genes, *ZBTB4* and *INPP5E* (highlighted in red), hypomethylation of the strongest significant CUD-associated CpG site and increased transcript levels are observed. **c** Integrated visualization of functional genomic datasets for *ZBTB4* and *INPP5E* gene loci. CUD-associated genomic variants (SNPs p<0.05 from³⁰), CUD-associated CpG sites (p<0.05 from²²), RNA-seq data and intron clusters (q<0.05) from the present study were visualized together with ENCODE ChIP-seq data for different chromatin marks in human dorsolateral prefrontal cortex.

322

Multi-Omics Factor Analysis confirms cell junction, synaptic signaling, and neurogenesis as important
 biological processes in CUD

325 The integration of DNA methylation and gene expression data as described above is based on results 326 of the EWAS, DE, and AS analyses which is one possible way of integrating multiple omics datasets. In 327 addition, multi-omics analysis tools such as MOFA enable an integrated analysis of omics datasets in a 328 single statistical framework. Using MOFA on our DNA methylation and gene expression data from BA9, 329 we identified one factor representation of the multi-omics dataset (factor 9) that was significantly 330 correlated with CUD (r=-0.48, p=0.02) and age (r=0.47, p=0.02, Supplementary Fig. S5a+S5b). Factor 331 9 displayed significantly smaller factor values in CUD cases compared to individuals without CUD in a 332 Wilcoxon test (p=0.02, Supplementary Fig. S5c). When we extracted the CpG sites with the strongest 333 weights on factor 9, cg23859635 annotated to MTA3 was the CpG site with the strongest positive weight 334 on factor 9 (w=0.31), while cg24621354 in the gene TES displayed the strongest negative weight (w=-335 0.33, Supplementary Fig. S5d, Supplementary Table S13). In the gene expression dataset, the small 336 GTPase RAB6A had the strongest positive weight (w=0.07), while HIVEP2 had the strongest negative 337 weight (w=-0.05) on factor 9 (Supplementary Fig. S5e, Table S13). Results of a GSEA on negative 338 expression weights on factor 9 revealed FDR-significant (q<0.05) enrichment for synaptic signaling, cell 339 junction organization, and neurogenesis pathways, confirming the results from the previous analyses. 340 In contrast, GSEA on positive expression weights revealed enrichment for cellular respiration and small 341 molecule metabolic processes (Supplementary Fig. S5f, Supplementary Table S14). When we used 342 missMethyl to investigate the biological pathways for DNA methylation features with strong weights on 343 factor 9, we detected enrichment for similar biological pathways as in the analysis of expression 344 features. While none of the enrichment results remained FDR-significant after multiple testing correction, 345 strongest enrichment for CpG sites with negative weights on factor 9 was detected for intracellular 346 calcium concentration regulation and synaptic vesicle related processes (Supplementary Fig. S5g, 347 Supplementary Table S15). The pathways showing the strongest enrichment for the positive weight 348 CpG sites were related to monocarboxylic acid and specifically, lactate transmembrane transporter 349 activity, and ER stress pathways (Supplementary Fig. S5h, Supplementary Table S15).

Integrative functional analysis reveals functional modules related to neurotransmission, cell
 differentiation, cell junction organization, and fatty acid metabolism

352 In an integrative functional analysis approach, we used all available information from our study on DNA 353 methylation, gene expression, and alternative splicing alterations in CUD to identify potential 354 convergence of association results at the pathway level in BA9. We thus performed a GO enrichment 355 analysis based on 10 curated lists with CUD-associated genes derived from EWAS, DE analysis, 356 alternative splicing analysis, WGCNA modules based on DNA methylation and expression data, and 357 MOFA (Supplementary Table S16). In the enrichment map for GO terms, we identified several functional 358 modules where the same biological pathway was detected for multiple gene lists at FDR-adjusted 359 statistical significance (q<0.05) indicating convergence of the results from different analysis approaches 360 (Supplementary Fig. S6). The two largest functional modules (FM) contained pathways involved in 361 neurotransmission and synaptic signaling (FM1), while FM2 was enriched for neuron and glial cell 362 differentiation, growth, and morphogenesis processes. Two further prominent modules were related to 363 synapse and cell junction organization (FM3) and fatty acid metabolism (FM4).

364

365 **Discussion**

366 By applying a multi-omics data integration approach on DNA methylation and gene expression data 367 from postmortem human brain tissue we aimed for a deeper understanding of the neurobiology of CUD 368 in the human prefrontal cortex. At the gene level, our differential expression analysis suggests two 369 candidates, FKBP4 and HSPA6, which were replicated as nominally significancant findings in two 370 independent cohorts. In addition, our multi-omics analyses highlight ZBTB4 and INPP5E, that were 371 consistently altered across omics analyses in BA9 and displayed consistent upregulation patterns in 372 independent replication datasets. At the pathway level, we found converging evidence for CUD-373 associated DNAm and transcriptional alterations that were related to neurotransmission, fatty-acid 374 metabolism, and changes in neuronal morphology.

375

Analysis of the transcriptome in BA9 revealed *ZFAND2A* as the DEG showing the strongest association with CUD. *ZFAND2A* is a canonical heat shock gene in humans encoding a zinc-finger containing protein that is involved in the regulation of proteasomal protein degradation^{31,32}. It was further identified as a DEG in a study on transcriptomic signatures of Alzheimer's disease (AD)³³. Another AD-related finding emerged in co-expression network analysis. APOE showed the strongest connectivity in the PPI network for module yellow genes and has been intensively characterized due to its association with age of onset in AD³⁴. While SUDs and neurodegenerative disorders such as AD depict different neuropsychiatric disorders based on the current understanding of disease mechanisms, CUD and AD share brain atrophic changes as a clinical symptom³⁵ and our results suggest that there might be shared molecular mechanisms involved.

386

387 Previous studies have identified differential alternative splicing in alcohol use disorder²⁵ and opioid use 388 disorder (OUD)²⁶ in the human brain, however, RNA splicing alterations have not been characterized in 389 human CUD so far. In the differential alternative splicing analysis, we found N=98 statistically significant 390 genes containing AS intron clusters. Interestingly, among our top findings, we found Bridging Integrator 391 1 (BIN1) for which differential alternative splicing in the brain has been described in OUD. BIN1 was the 392 only differential AS gene in OUD that was conserved across all investigated brain regions; dIPFC, NAc, 393 and midbrain²⁶. Further, AS events in Bin1 were identified in the mouse brain in a study on splicing 394 alterations associated with cocaine self-administration²⁷. As dendrite and axon morphogenesis 395 processes were among the enrichment results for AS genes in BA9, we hypothesize that AS is directly 396 related to neuroplastic changes in the CUD brain. Mechanistically, AS processes change the abundance 397 of transcript isoforms with different biological functions that might contribute to the neuroadaptations in 398 CUD. We explored the mechanism of spliceosomal gene expression alterations as a potential 399 contributor to differential AS events in CUD. Exposure to cocaine was previously hypothesized to alter 400 spliceosomal gene expression²⁹ and our results suggest spliceosomal genes such as HSPA6 and 401 HSP1A1 as DEGs in BA9. As spliceosomal gene alterations were also detected in the replication 402 analysis with HSPA6 as a shared upregulated DE gene across studies, AS events might be an important 403 mechanism in CUD contributing to neurobiological changes in the PFC.

404

In the last step of the RNA-sequencing analysis, we aimed to address the urgent need for novel pharmacotherapeutic approaches for the treatment of CUD by performing a drug repositioning analysis. We detected glucocorticoid receptor-targeting drugs having consistently negative connections with the CUD expression profile in BA9. In addition, *FKBP4*, an important regulator of glucocorticoid receptor signaling was identified as a conserved upregulated DEG in CUD based on three independent dIPFC datasets. FKBP4 has a key role in the nuclear translocation of the glucocorticoid receptor, as it replaces FKBP5 upon cortisol binding to the receptor complex leading to its nuclear translocation³⁶. 412 Pharmacological targeting of glucocorticoid receptor signaling was tested in rodent models of cocaine 413 addiction ³⁷⁻³⁹. Reduced behavioral response to cocaine was observed when glucocorticoid receptor 414 antagonists such as mifepristone were applied³⁷. In contrast, corticosterone was shown to promote 415 cocaine intake in rats^{38,39}. In the drug repositioning analysis, results for glucocorticoid receptor agonists 416 were more prominent compared to antagonists which appears to be in conflict with previous literature. 417 However, glucocorticoid receptor antagonists such as mifepristone also displayed significant negative 418 connectivity scores with the BA9 expression signature supporting previous findings. Further, synthetic 419 glucocorticoid receptor agonists such as dexamethasone were shown to impair cocaine self-420 administration in rats³⁸ indicating a more complex relationship between the endogenous glucocorticoid 421 system and exogenously applied glucocorticoid receptor targeting drugs. We thus suggest that 422 glucocorticoid receptor targeting drugs should be further investigated for their potential use as a 423 pharmacotherapy in CUD.

424

425 Using multi-omics data integration, we identified two genes, ZBTB4 and INPP5E, for which CUD-426 associated alterations were consistently detected across DNAm, gene expression, and alternative 427 splicing analyses. Both genes contained a hypomethylated CpG site, stronger transcript expression was 428 found in individuals with CUD, and significant differentially spliced intron clusters were identified. Despite 429 being strongly expressed in the brain and most prominently in neurons⁴⁰, the role of ZBTB4 in 430 neuropsychiatric disorders remains poorly understood. However, due to the DNA binding capacity and 431 its role as a transcriptional repressor, ZBTB4 deregulation in CUD could lead to downstream expression 432 changes of its target genes. Further, protein-protein interaction data suggests interaction of ZBTB4 with 433 the transcription factor PRDM5 as well as with the AP2M1 and AP2A1 subunits of the adapter protein 2 434 (AP-2) complex that is involved in endocytosis of neurotransmitter receptors in neurons^{41,42}. The second 435 finding at the gene level, INPP5E, encodes a phosphatidylinositol-phosphatase specific to cilia and 436 INPP5E mutations were found in Joubert syndrome which is characterized by cerebellar and cerebral 437 malformation⁴³. A possible link to CUD provide neuronal primary cilia, known as key signaling hubs on 438 somata enriched for G-protein-coupled receptors (GPCRs)⁴⁴. As INPP5E is required for proper 439 trafficking of GPCRs along ciliary microtubules⁴⁵, deregulation of *INPP5E* might lead to aberrant ciliary 440 signaling that has recently gained attention in the addiction field: cell type-specific ablation of neuronal 441 primary cilia in mice was shown to affect body weight as well as locomotor response to psychostimulants

such as cocaine⁴⁶ and amphetamine⁴⁷. In humans, further studies on INPP5E are required to evaluate
its role in SUDs.

444

445 Evaluating the convergence of results at the pathway level revealed widespread molecular alterations 446 in synaptic signaling represented by functional module FM1 in the GO enrichment analysis. Our findings 447 are well in line with previous literature that reported on cocaine-associated DNAm and expression 448 changes in genes involved in neurotransmission^{14-16,18,48}. The observed overrepresentation of neuronal 449 marker genes in the upregulated DEGs together with the non-neuronal marker gene enrichment in the 450 downregulated DEGs further suggests a particular importance of CUD-associated expression changes 451 in altering neurotransmission. In a study on CUD-associated gene expression changes in neuronal 452 nuclei of the human dIPFC²¹, the authors found a WGCNA co-expression module that was significantly 453 associated with CUD and was enriched for GTPase signaling and neurotransmitter transport that well 454 matches our results in BA9. Neuronal function thus appears to be strongly influenced by altered 455 epigenetic and transcriptional programs in the CUD brain.

456

Functional modules FM2 and FM3 were related to pathways involved in neuron, synapse, and axon morphogenetic processes. This is supported by literature from animal models of CUD, where alterations in dendritic branches and spine density were observed in the PFC of cocaine self-administering rats⁴⁹. Even a single cocaine exposure was sufficient to reduce dendritic spine density in neurons⁵⁰. In summary, brain morphological changes depict an interesting link between molecular and behavioral aspects of addiction as neuroplastic changes are the basis of neurocircuit alterations in the SUD brain that are related to compulsive drug-seeking and relapse⁵¹.

464

465 Another converging finding were metabolic changes related to fatty acid metabolism (FM4). This finding 466 was especially prominent in the CUD-associated WGCNA module yellow where we found a functional 467 module of pathways related to fatty acid metabolism. Further, results from MOFA suggested gene 468 expression changes related to the electron transport chain as another key metabolic pathway alteration. 469 This is supported by findings from animal models of cocaine addiction where a downregulation of 470 glycolysis and oxidative phosphorylation were observed in the brain⁵² while fatty acid metabolism genes 471 were upregulated⁵³. It has to be noted that metabolic changes in CUD are most likely not brain-spercific 472 but also appear on a systemic level as individuals with CUD were found to have reduced body fat in

473 comparison to a healthy control group⁵⁴. To follow up on this finding, future studies should evaluate if
474 interfering with fatty acid metabolism could depict a therapeutic strategy in CUD as a ketogenic diet has
475 been shown to alter the behavioral response to cocaine in rats⁵⁵.

476

477 There are some limitations that apply to our multi-omics study of CUD. First, depicting an inherent 478 limitation of analyses in human postmortem brain tissue, our cross-sectional analysis design can only 479 reflect the endpoint of CUD limiting the identification of dynamic changes in DNAm and gene expression 480 during the disease course. Second, considering the sample size and the few DEGs at transcriptome-481 wide significance, it remains unclear whether the findings are generalizable to the general population 482 highlighting the need for studies in larger and more diverse cohorts. Third, while the homogeneity of our 483 sample consisting of only males from EA ancestry is a strength in statistical analysis, sex-specific and 484 ancestry-related molecular signatures of CUD remain an open question. At least in the analysis of the 485 more diverse replication cohorts we were able to show comparable CUD-associatied gene expression 486 patterns when compared to our discovery cohort.

487

In summary, our study identifies novel associations with CUD at the gene level, confirms these on the multi-omics level, and suggests differential alterative splicing as an important molecular hallmark of CUD in the human prefrontal cortex. At the same time, our study supports previous findings of synaptic signaling alterations that have been robustly detected when investigating the neurobiological effects of cocaine. We highlight drugs targeting glucocorticoid receptor signaling to be further tested as a treatment for CUD.

494 Author contributions

- 495 Conceptualization, E.Z., L.Z., M.R., R.S., and S.H.W.; Methodology, E.Z., H.B., J.F., and L.Z.;
- 496 Resources, G.T., N.M., A.C.H., J.C-D., N.F-C., B.C., and J.M.O.; Data curation, E.Z., D.A., H.B., D.A-
- 497 B., J.J.M-M., and L.Z.; Data Analysis, E.Z., H.B., D.A., D.A-B., L.Z., and J.M.M-M., Investigation, E.Z.,
- 498 H.B., A.C.H., M.R., R.S., S.H.W, and L.Z.; Writing Original Draft, E.Z., H.B.; Writing Reviewing &
- 499 Editing, E.Z., H.B., D.A., D.A-B, J.M-M., J.F., N.M., G.T., J.C-D., N.F-C., B.C., J.L.M-M., A.C.H., M.R.,
- 500 R.S., S.H.W., and L.Z.; Supervision, J.F., M.R., and R.S., J.M.O., L.Z., and S.H.W; Project
- 501 Administration, R.S., A.C.H., M.R. and S.H.W., Funding Acquisition, R.S., A.C.H., M.R., and S.H.W.

502 **Competing interests**

503 The authors declare that there are no competing interests.

504

505 **Data availability statement**

Raw methylation data is deposited in the European Genome Phenome Archive (EGA) under accession number EGAS00001006828 (https://ega-archive.org/studies/EGAS00001006826). RNA-sequencing data has been uploaded to the EGA will be listed with an accession number by the time of publication.

509

510 **Code availability statement**

All original code used for data analysis and figure preparation will be available in a GitHub repository (https://github.com/lzillich/BA9_multi_omics) by the time of publication.

513

514 **Ethics statement**

515 Postmortem human brain tissue was obtained from the Douglas Bell Canada Brain Bank where tissue 516 sampling is performed based on their established ethical guidelines. Our multi-omics study was 517 approved by the Ethics Committee II of the University of Heidelberg, Medical Faculty Mannheim, 518 Germany, under the register number 2021-681.

- 519
- 520
- 521

522 Funding

523 Funding supporting this study was provided by the German Federal Ministry of Education and Research 524 (BMBF) within the e:Med research program SysMedSUDs: "A systems-medicine approach toward 525 distinct and shared resilience and pathological mechanisms of substance use disorders" (01ZX01909 526 to R.S., M.R., A.C.H., and S.H.W.). In addition, by the Deutsche Forschungsgemeinschaft (DFG) 527 through the collaborative research centre TRR265: "Losing and Regaining Control over Drug Intake"⁵⁶ 528 (Project ID 402170461 to S.H.W., R.S., A.C.H. and M.R.), the Hetzler Foundation for Addiction Research 529 (to A.C.H.), the ERA-NET program: Psi-Alc (01EZ1908), Spanish 'Ministerio de Ciencia, Innovación y 530 Universidades' (PID2021-1277760B-I100, to B.C.), 'Generalitat de Catalunya/AGAUR' (2021-SGR-531 01093, to B.C.), ICREA Academia 2021, 'Fundació La Marató de TV3' (202218-31, to B.C.) and from 532 'Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas' (PNSD-2020I042, 533 to N.F.-C.). The project has been carried out using the Mannheim (CIMH) infrastructure of the German 534 Center for Mental Health (DZPG).

535

536 Methods

537 **Postmortem human brain tissue**

538 The sample of human postmortem brain tissue of BA9 was obtained from the Douglas Bell Canada 539 Brain Bank (DBCBB). Inclusion criteria were age > 18 and a diagnosis of cocaine dependence based 540 on DSM-IV. Throughout this study, we will nevertheless use the more recent terminology from DSM-5 541 i.e., cocaine use disorder. Individuals were excluded from the study if they were diagnosed with severe 542 neurodevelopmental or psychiatric disorders other than depressive disorders or had received additional 543 diagnoses of substance use disorders other than alcohol use disorder. All included subjects were male 544 and of European American descent. Demographic information for the cohort of N=42 BA9 tissue donors 545 is described in²² and for the subset of N=25 individuals with RNA-seq data in Table S1.

546

547 **DNA methylation data generation**

548 DNA extraction was performed as described in²². In brief, DNA was extracted from the full set of N=42 549 BA9 samples using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). The epigenome-wide 550 DNAm profile was determined using the Illumina MethylationEPIC BeadChip v1 (850k) (Illumina, San 551 Diego, CA, USA). During sample processing and analysis of DNAm levels, randomization was applied 552 based on CUD status and known comorbidities such as AUD and depressive disorders.

553

554 Generation of gene expression data

Using the miRNAeasy Mini extraction Kit (Qiagen, Hilden, Germany), total RNA was extracted from the N=42 BA9 samples using ~5mg of frozen tissue from each individual. The RNA integrity number (RIN) was measured using a TapeStation 4200 (Agilent, Santa Clara, CA, USA) resulting in a total of N=25 samples remaining for RNA sequencing (RIN > 5.5). Following ribosomal RNA (rRNA) depletion, libraries were prepared using the NEBNext Ultra II Directional RNA Library Prep Kit (New England Biolabs, Ipswich, MA, USA) followed by sequencing with an average of 60 million read pairs (2x100bp) per sample. RNA sequencing was performed using an Illumina NovaSeq 6000 device.

562

563 Statistical analyses

All statistical analyses in the R programming environment were performed using R version 4.2.1. If not otherwise stated, adjustment for multiple testing was performed using the Benjamini-Hochberg (FDR) procedure⁵⁷. An analysis workflow for the multi-omics study of DNA methylation and gene expression in
 CUD is shown in Supplementary Fig. S7.

568

569 **DNA methylation analysis**

570 Methylation data was analyzed as part of the Poisel, et al. ²² study where a detailed description of the 571 analysis pipeline can be found in the methods section. In brief, DNA methylation levels were 572 preprocessed using an in-house quality control (QC) pipeline based on CPACOR⁵⁸. The neuronal cell 573 fraction was estimated based on the Houseman algorithm⁵⁹ using a dIPFC reference dataset⁶⁰. Quantile-574 normalized beta values were derived from raw-intensities, followed by logit-transformation to M values 575 of methylation. An epigenome-wide association study (EWAS) was performed using a linear regression 576 model while adjusting for covariates that have a known effect on DNA methylation such as age, 577 postmortem interval (PMI), pH of the brain tissue, neuronal cell fraction, comorbid depressive and/or 578 alcohol use disorder, and technical factors. Downstream analyses based on the results of the EWAS 579 included the identification of differentially methylated regions (DMRs), a gene ontology enrichment 580 analysis using CUD-associated CpG sites (passoc<0.001), and a network analysis in WGCNA to evaluate 581 CUD-associated co-methylation modules.

582

583 Gene expression analysis

584 Sequencing quality metrics were inspected using FastQC v.0.12.1 confirming all 25 fastq files to be used 585 in further analysis. Reads were mapped to the GRCh38 genome primary assembly using STAR 586 v.2.7.10b⁶¹. Quantification of features was performed using the featureCounts implementation in the R 587 package Rsubread v.2.12.362 with the genome annotation gtf-file v.43 from GENCODE 588 (https://www.gencodegenes.org). The raw count matrix was imported in DESeq2 v.1.38.3⁶³ and 589 differential expression (DE) testing was performed while adjusting for the covariates age, PMI, brain pH 590 and RIN in the DESeq2 experimental design formula. The distribution of resulting p-values was 591 assessed in a quantile-quantile plot to evaluate potential genomic inflation (Fig. S1A). Fold-change cut-592 offs for DEGs were an absolute log2 fold change of larger than 0.07, corresponding to a 5% change in 593 transcript abundance. Statistical significance cut-offs were p<0.05 for nominal significance and q<0.05 594 for a 5% FDR-adjusted significant association with CUD. All covariates included in the DESeq2 model 595 are known to influence the gene expression profile and were confirmed in a variance partition analysis 596 in our dataset using the R package variancePartition v.1.28.7 (Supplementary Fig. S1a). As comorbid 597 MDD and AUD explained only minimal variance in the expression data and only 25 of the 42 samples 598 were available in the expression analysis, MDD and AUD were not included as covariates in the 599 statistical model. A sensitivity analysis was performed including MDD and AUD as covariates 600 (Supplementary Fig. S1b) confirming a strong correlation between the log2 fold-changes of the 601 nominally significant results.

602

603 Cell-type deconvolution analysis

604 Based on reference signatures of gene expression derived from single-cell studies, the distribution of 605 cell types in bulk expression data can be inferred using cell-type deconvolution algorithms such as 606 CIBERSORT⁶⁴. We used a curated set of cell type-specific marker genes of the human prefrontal cortex 607 based on a study from Yu and He⁶⁵ where a gene was required to have a 10-fold stronger expression 608 in a specific cell type compared to all other cell types to be considered a marker gene. DESeq2-609 normalized counts of the BA9 expression dataset were used and cell type deconvolution was performed 610 using the CIBERSORT R script v1.04. To test for significant differences in cell type distribution in 611 samples from individuals with and without CUD, we performed a Bayesian estimation of the difference 612 in means and evaluated the 95% high-density interval. The Bayesian testing was based on BEST⁶⁶ as 613 implemented in the R package BayesianFirstAid v.0.1. Further, an overlap analysis of DEGs in cell type 614 markers was performed in GeneOverlap v.1.34.0⁶⁷ using the 10-fold marker gene list from⁶⁵ in a Fisher 615 test.

616

617 Functional enrichment analysis

To characterize altered biological functions related to the observed gene expression differences, we performed a gene set enrichment analysis (GSEA) for Gene Ontology (GO) terms using the gseGO function from the R package clusterProfiler v.4.6.2⁶⁸. The DESeq2 Wald statistic defined as the log2FC divided by its standard error was used for ranking of the results. A significance threshold of q<0.05 (5% FDR) was considered statistically significant. Results of the GSEA were visualized using the emapplot function in enrichplot v.1.18.3.

624

625 Weighted gene co-expression network analysis (WGCNA)

To identify CUD-associated co-expression patterns, we constructed co-expression modules using network analysis in WGCNA (R package v.1.72.1)⁶⁹ and related them to CUD and other phenotypic 628 variables available in the DBCBB cohort. Using the input matrix of normalized and variance stabilization 629 transformed (vst) gene counts from DESeq2, a soft power threshold of 9 was estimated to achieve the 630 criterion of scale free topology (R²>0.85). For the construction of networks, we used the parameters 631 minModuleSize=10, mergeCutHeight=0.25, and maxBlockSize=36,000. The Pearson correlation of the 632 module eigengene derived from each of the resulting n=27 co-expression modules with the phenotypes 633 of interest including CUD was calculated to identify significant associations of the modules with 634 phenotypes (Fig. S3A). Downstream analyses of modules significantly associated with CUD included a 635 GO enrichment analysis using the genes assigned to the modules using the full genome as the 636 background. Next, module genes were ranked by the product of gene significance*module membership 637 to identify hub genes. The top 10% of module hub genes were further investigated by constructing 638 protein-protein interaction (PPI) networks. For this, Cytoscape v.3.9.1⁷⁰ with stringApp v.1.7.0⁷¹ was 639 used. A detailed description of the PPI visualization settings in Cytoscape is found in²².

640

641 Replication analysis of differential expression results

642 Replication analysis of CUD-associated DEGs was performed in two independent datasets where RNA-643 seq data from postmortem human brain tissue of the prefrontal cortex from individuals with and without 644 CUD was available. As the first replication dataset, BA9 bulk RNA-sequencing data from N=7 individuals 645 with CUD and N=14 control individuals originating from the National PTSD Brain Bank (NPBB)⁷² was 646 used. Phenotypic information for the BA9 replication cohort is shown in Table S17. RNA-seq data 647 sequenced and pre-processed as described in 73 was analyzed for CUD-associated differential gene 648 expression in DESeq2 using donor age, sex, PMI, and RIN as covariates. The second replication cohort 649 was based on a neuronal-specific RNA-sequencing dataset (GEO accession number: GSE99349) as 650 described in ²¹. In this study, neuronal nuclei were isolated from postmortem human brain tissue of the 651 Brodmann Area 46 subregion of the dIPFC that is laterally adjacent to BA9. Here, bulk RNA-seq data 652 was generated from N=19 individuals with CUD and N=17 without CUD from a male mixed ancestry 653 cohort originating from the University of Miami Brain Bank (MBB). Raw sequencing data from the 654 replication cohort was downloaded from GEO and processed using the same analysis pipeline as in the 655 BA9 discovery sample: 1) mapping using STAR, 2) quantification using featureCounts, and 3) DE 656 analysis in DESeq2. For the replication analysis in MBB data, we used the same statistical model as in 657 the discovery analysis with differential expression testing for CUD while adjusting for donor age, RIN, 658 pH, and PMI. To explore the results, we first performed an overlap analysis of nominally significant CUD-

659 associated DEGs (p<0.05) identified in the three datasets. Second, a targeted look-up of effect sizes 660 (log2FC) and association p-values was performed for overlapping DEGs across datasets and for the top 661 findings from the BA9 discovery sample, ZBTB4 and INPP5E. As an additional replication approach, we 662 performed rank-rank hypergeometric overlap (RRHO) using the R package RRHO2 v.1.0⁷⁴ to evaluate 663 convergent and divergent expression patterns at the transcriptome-wide scale between studies. RRHO 664 scores were generated based on full differential expression statistics from discovery and replication 665 datasets followed by the evaluation of overlapping signatures between studies using the hypergeometric 666 testing procedure as implemented in RRHO2.

667

668 Signature-based drug repositioning analysis

669 With the top 150 upregulated and downregulated genes ranked by the DESeq2 test statistic from the 670 differential expression analysis, the maximum input size in the Connectivity Map (CMap) query tool 671 (https://clue.io/query, software version 1.1.1.43) was used to evaluate the connectivity of expression 672 signatures (Table S8). CMap query uses the L1000 assay from the NIH LINCS project 673 (https://lincsproject.org/) as a drug-gene expression relationship database. In L1000, expression 674 changes for a representative set of 978 landmark transcripts are measured in response to treatment 675 with a perturbagen such as a pharmaceutical drug⁷⁵. In addition to the connectivity scores for individual 676 perturbagens, CMap also provides information on perturbagen classes and a GSEA output for pathways 677 and drug targets. Normalized connectivity scores and FDR-adjusted p-values for perturbagens and 678 GSEA results were obtained from the CMap query tool and visualized as waterfall plots in R using 679 ggplot2 v.3.4.2.

680

681 Differential splicing analysis

682 Alternative splicing was evaluated using the annotation-free quantification approach of RNA splicing in 683 LeafCutter v.0.2.9²⁸. First, raw sequencing data were aligned to the GRCh38 reference genome using 684 STAR with an adapted 2-pass mapping procedure. For this, the first mapping step was performed using 685 a regular gtf-file derived genome index. The resulting splice junctions (SJ out.tab-files) from the N=25 686 samples were combined and filtered so that non-canonical junctions, junctions that were supported by 687 less or equal than 2 uniquely mapping reads, annotated junctions already covered by the gtf-file, and 688 duplicated junctions were removed. Using the filtered splice junction output, a modified genome index 689 was derived using STAR in genomeGenerate mode. This extended genome index containing

690 information on gene annotation and splice junctions was used in the second mapping step resulting in 691 the final bam-file output after mapping. Generation of junc-files, intron clustering, and differential intron 692 excision analysis was performed as outlined by the authors of leafCutter 693 (https://davidaknowles.github.io/leafcutter/) while including age, PMI, pH, and RIN as covariates into the 694 Dirichlet-Multinomial generalized linear model. Default settings were used in the leafcutter_ds.R script 695 i.e. maximum cluster size =10, minimum samples per intron = 5, minimum samples per group = 3, and 696 a minimum coverage of 20 reads. The differential intron excision analysis results in an estimate for the 697 change in the percent spliced in measure (ΔPSI) for each intron in a cluster and an FDR-adjusted p-698 value for the cluster in which the differential splicing events were detected. Differential splicing events 699 in clusters with |dPSI| > 0.025 and an FDR-adjusted q-value<0.05 were considered statistically 700 significant²⁶. Visualizations for the differentially spliced clusters and genes were created using the leafviz 701 extension in leafCutter. GO enrichment analysis for genes containing differentially alternatively spliced 702 intron clusters was performed using the enrichGO function with GO "BP" ontology terms in 703 clusterProfiler.

704

705 Integrative gene locus analysis

706 Integrated visualization of functional genomics data was performed using SparK v.2.6.2⁷⁶. Summary 707 statistics from a meta-analysis GWAS of cocaine dependence (CD) in an EA population (N=6,378)³⁰ 708 was used to cover SNPs that are associated with CD. The EWAS summary statistics from ²² were used 709 as the DNAm dataset. To prioritize the association results for visualization, SNPs and CpG sites with 710 nominal significant association p-value (p<0.05) were filtered from the GWAS and EWAS results. ChIP-711 seq datasets for different activating and repressing chromatin marks were downloaded from ENCODE⁷⁷ 712 as deposited in the Human Reference Epigenome Matrix for dorsolateral PFC in males: ENCFF241REN 713 (H3K4me1), ENCFF752EVS (H3K4me3), ENCFF866IWY (H3K27ac), ENCFF149DDW (H3K36me3), 714 ENCFF784SSN (H3K9me3), ENCFF167ASN (H3K27me3). BigWig files were converted to BedGraph 715 using the UCSC bigWigToBedGraph tool. Bam-files from the RNA-seq analysis were indexed using 716 samtools v.1.578 and then converted to BedGraph using the bamCoverage function from deeptools 717 v.3.5.3⁷⁹. For the genetic dataset, we performed an additional gene-based association analysis using 718 Multi-marker Analysis of GenoMic Annotation (MAGMA)⁸⁰. Here, we aimed to quantify the combined 719 association of all SNPs annotated to a gene of interest with CUD as the phenotype.

720

721 Multi-omics factor analysis

722 Multi-omics factor analysis (MOFA)⁸¹ was used to jointly analyze the DNAm and gene expression 723 datasets in BA9 aiming for the identification of CUD-associated factors. The factor analysis framework 724 enables an improved characterization of gene and pathway alterations across different omics datasets 725 by investigating the contribution of each omics view such as DNAm or gene expression to a learned 726 factor. Downstream analyses such as GSEA enable the analysis of biological functions that are 727 associated with a factor based on the factor loading of features such as genes that contribute to the 728 biological pathway. As the DNAm input dataset for MOFA (R package v.1.3.1), we used methylation M-729 values from the 20,000 most variant promoter CpG sites (TSS200 and TSS1500 annotations) under the 730 assumption of their prominent role in regulating transcription levels of nearby genes. Methylation data 731 was extracted for the individuals that also had expression data available (N=25). For the expression 732 dataset, we used normalized and variance stabilization transformed counts from the 20,000 most variant 733 genes to obtain an equal number of features in each view. The MOFA model was trained on the matched 734 DNAm and expression data from N=25 individuals using default model options with a total of 10 factors 735 and the training options convergence mode = "slow", seed = 42, and maxiter=10,000. Association of 736 factors with phenotypes was evaluated using the correlate factors with covariates function. GSEA was 737 performed on negative and positive weights individually using the run enrichment function based on the 738 c5.go.bp.v2023.1.Hs.symbols.gmt gene set reference file from MSigDB⁸². Functional characterization 739 of DNAm weights was performed by subsetting the top 2.5% of CpG sites from both sides of the weight 740 distribution on factor 9 resulting in N=500 CpG sites with strongest positive and negative weights on 741 factor 9, respectively. Next, GO enrichment analysis was performed in missMethyl v.1.33.1 using the 742 full set of N=20,000 CpG sites as background.

743

744 GO enrichment analysis of CUD-associated gene sets

Convergence of CUD association signals at the pathway level was evaluated by pathway enrichment analysis for GO terms using the enrichGO function on the GO "BP" ontology in the compareCluster functionality of clusterProfiler. A total of 10 gene lists were included in the input dataset: 1) CUDassociated CpG sites (N=394, p>0.001) from the EWAS of CUD²², genes in the CUD-associated WGCNA methylation modules 2) blue (N=9,201), 3) steelblue (N=390), 4) brown (N=5,268), 5) brown4 (N=205), 6) nominally significant DEGs (N=1,057,p<0.05), 7) genes in the CUD-associated WGCNA expression module yellow (N=2,517), 8) AS genes (N=98, q<0.05), 9) MOFA methylation weights factor

- 752 9 (N=983 genes based on the 2.5 and 97.5 percentiles of the weight distribution for CpG sites), and 10)
- 753 MOFA methylation weights factor 9 (N=1,000 genes based on the 2.5 and 97.5 percentiles of the weight
- 754 distribution for genes). Pathways remaining statistically significant after FDR correction (q < 0.05) were
- 755 displayed in an enrichment map with a pie plot visualization scheme for GO terms that were repeatedly
- 756 identified for the different gene lists.
- 757

758 References

- 759 1 Degenhardt, L. et al. The global burden of disease attributable to alcohol and drug use in 195 760 countries and territories, 1990–2016: a systematic analysis for the Global Burden of 761 Disease Study 2016. The Lancet Psychiatry 5, 987-1012 (2018). 762 https://doi.org:10.1016/S2215-0366(18)30337-7
- 763 2 American Psychiatric Association & American Psychiatric Association, DSM-5 Task Force. 764 (2013). Diagnostic and statistical manual of mental disorders : DSM-5. Arlington, V. A. P. A.
- Kampman, K. M. The treatment of cocaine use disorder. Sci Adv 5, eaax1532 (2019). 765 3 766 https://doi.org:10.1126/sciadv.aax1532
- 767 4 Nestler, E. J. The neurobiology of cocaine addiction. Sci Pract Perspect 3, 4-10 (2005). 768 https://doi.org:10.1151/spp05314
- 769 5 Ersche, K. D. et al. Abnormal structure of frontostriatal brain systems is associated with 770 aspects of impulsivity and compulsivity in cocaine dependence. Brain 134, 2013-2024 (2011). 771 https://doi.org:10.1093/brain/awr138
- 772 6 Goldstein, R. Z. & Volkow, N. D. Drug addiction and its underlying neurobiological basis: 773 neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159, 1642-774 775 1652 (2002). https://doi.org:10.1176/appi.ajp.159.10.1642
- 7 Cox, J. & Witten, I. B. Striatal circuits for reward learning and decision-making. Nat Rev 776 Neurosci 20, 482-494 (2019). https://doi.org:10.1038/s41583-019-0189-2
- 777 8 Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet 778 Psychiatry 3, 760-773 (2016). https://doi.org:10.1016/s2215-0366(16)00104-8
- 779 9 Robison, A. J. & Nestler, E. J. Transcriptional and epigenetic mechanisms of addiction. Nature 780 Reviews Neuroscience 12, 623-637 (2011). https://doi.org:10.1038/nrn3111
- 781 10 Fernàndez-Castillo, N., Cabana-Domínguez, J., Corominas, R. & Cormand, B. Molecular 782 genetics of cocaine use disorders in humans. *Molecular Psychiatry* 27, 624-639 (2022). 783 https://doi.org:10.1038/s41380-021-01256-1
- 784 11 Baker-Andresen, D. et al. Persistent variations in neuronal DNA methylation following cocaine 785 self-administration and protracted abstinence in mice. Neuroepigenetics 4, 1-11 (2015). 786 https://doi.org:10.1016/j.nepig.2015.10.001
- 787 12 Anier, K., Malinovskaja, K., Aonurm-Helm, A., Zharkovsky, A. & Kalda, A. DNA methylation 788 regulates cocaine-induced behavioral sensitization in mice. Neuropsychopharmacology 35, 789 2450-2461 (2010). https://doi.org:10.1038/npp.2010.128
- 790 13 Gibney, E. R. & Nolan, C. M. Epigenetics and gene expression. Heredity 105, 4-13 (2010). 791 https://doi.org:10.1038/hdy.2010.54
- 792 Campbell, R. R. et al. Cocaine induces paradigm-specific changes to the transcriptome within 14 793 the ventral tegmental area. Neuropsychopharmacology 46, 1768-1779 (2021). 794 https://doi.org:10.1038/s41386-021-01031-4
- 795 Savell, K. E. et al. A dopamine-induced gene expression signature regulates neuronal function 15 796 and cocaine response. Science Advances 6, eaba4221 797 https://doi.org:10.1126/sciadv.aba4221
- 798 16 Li, M. et al. Dynamic Expression Changes in the Transcriptome of the Prefrontal Cortex after 799 Repeated Exposure to Cocaine in Mice. Front Pharmacol 8, 142 (2017). 800 https://doi.org:10.3389/fphar.2017.00142
- 801 17 Teague, C. D. & Nestler, E. J. Key transcription factors mediating cocaine-induced plasticity in 802 the nucleus accumbens. Molecular Psychiatry 27, 687-709 (2022). 803 https://doi.org:10.1038/s41380-021-01163-5
- 804 18 Vaillancourt, K. et al. Methylation of the tyrosine hydroxylase gene is dysregulated by cocaine dependence in the human striatum. iScience 24, 103169 (2021). 805 806 https://doi.org:10.1016/j.isci.2021.103169

- 80719Vaillancourt, K. *et al.* Cocaine-related DNA methylation in caudate neurons alters 3D808chromatin structure of the IRXA gene cluster. *Mol Psychiatry* **26**, 3134-3151 (2021).809https://doi.org:10.1038/s41380-020-00909-x
- 81020Mews, P. et al. Convergent abnormalities in striatal gene networks in human cocaine use811disorder and mouse cocaine administration models. Science Advances 9, eadd8946 (2023).812https://doi.org:doi:10.1126/sciadv.add8946
- 81321Ribeiro, E. A. et al. Gene Network Dysregulation in Dorsolateral Prefrontal Cortex Neurons of
Humans with Cocaine Use Disorder. Sci Rep 7, 5412 (2017). https://doi.org:10.1038/s41598-815017-05720-3
- 816 22 Poisel, E. *et al.* DNA methylation in cocaine use disorder–An epigenome-wide approach in the human prefrontal cortex. *Frontiers in Psychiatry* 14 (2023).
 818 https://doi.org:10.3389/fpsyt.2023.1075250
- 819 23 Van Booven, D. *et al.* Alcohol use disorder causes global changes in splicing in the human
 820 brain. *Transl Psychiatry* **11**, 2 (2021). <u>https://doi.org:10.1038/s41398-020-01163-z</u>
- Li, R. *et al.* RNA alternative splicing impacts the risk for alcohol use disorder. *Molecular Psychiatry* (2023). <u>https://doi.org:10.1038/s41380-023-02111-1</u>
- Huggett, S. B., Ikeda, A. S., Yuan, Q., Benca-Bachman, C. E. & Palmer, R. H. C. Genome-and transcriptome-wide splicing associations with alcohol use disorder. *Sci Rep* 13, 3950 (2023). <u>https://doi.org:10.1038/s41598-023-30926-z</u>
- 82626Huggett, S. B., Ikeda, A. S., McGeary, J. E., Kaun, K. R. & Palmer, R. H. C. Opioid Use827Disorder and Alternative mRNA Splicing in Reward Circuitry. Genes (Basel) 13 (2022).828https://doi.org:10.3390/genes13061045
- Xu, S.-J. *et al.* Chromatin-mediated alternative splicing regulates cocaine-reward behavior.
 Neuron 109, 2943-2966.e2948 (2021). <u>https://doi.org:10.1016/j.neuron.2021.08.008</u>
- Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nature Genetics* 50, 151-158 (2018). <u>https://doi.org:10.1038/s41588-017-0004-9</u>
- Huggett, S. B. & Stallings, M. C. Cocaine'omics: Genome-wide and transcriptome-wide
 analyses provide biological insight into cocaine use and dependence. *Addict Biol* 25, e12719
 (2020). <u>https://doi.org:10.1111/adb.12719</u>
- 836 30
 837 Cabana-Domínguez, J., Shivalikanjli, A., Fernàndez-Castillo, N. & Cormand, B. Genome-wide association meta-analysis of cocaine dependence: Shared genetics with comorbid conditions.
 838 *Prog Neuropsychopharmacol Biol Psychiatry* 94, 109667 (2019).
 839 https://doi.org:10.1016/j.pnpbp.2019.109667
- Rossi, A. *et al.* The Proteasome Inhibitor Bortezomib Is a Potent Inducer of Zinc Finger AN1type Domain 2a Gene Expression: ROLE OF HEAT SHOCK FACTOR 1 (HSF1)-HEAT
 SHOCK FACTOR 2 (HSF2) HETEROCOMPLEXES*. *Journal of Biological Chemistry* 289,
 12705-12715 (2014). https://doi.org/10.1074/jbc.M113.513242
- Lee, D., Takayama, S. & Goldberg, A. L. ZFAND5/ZNF216 is an activator of the 26S
 proteasome that stimulates overall protein degradation. *Proceedings of the National Academy* of *Sciences* 115, E9550-E9559 (2018). https://doi.org:10.1073/pnas.1809934115
- Shippy, D. C. & Ulland, T. K. Exploring the zinc-related transcriptional landscape in
 Alzheimer's disease. *IBRO Neurosci Rep* 13, 31-37 (2022).
 https://doi.org:10.1016/j.ibneur.2022.06.002
- 34 Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nature Reviews Neurology* **15**, 501-518
 852 (2019). <u>https://doi.org:10.1038/s41582-019-0228-7</u>
- 853 35
 854 Brsche, K. D., Jones, P. S., Williams, G. B., Robbins, T. W. & Bullmore, E. T. Cocaine
 854 dependence: a fast-track for brain ageing? *Mol Psychiatry* 18, 134-135 (2013).
 855 https://doi.org:10.1038/mp.2012.31
- Bornone-induced switching of FKBP51 and FKBP52 immunophilins. *J Biol Chem* 277, 4597-4600 (2002). https://doi.org.10.1074/jbc.C100531200
- 85937Deroche-Gamonet, V. *et al.* The glucocorticoid receptor as a potential target to reduce cocaine
abuse. *J Neurosci* 23, 4785-4790 (2003). https://doi.org:10.1523/jneurosci.23-11-04785.2003
- 38 John, R. M., David, S. & Nick, E. G. Corticosterone Facilitates the Acquisition of Cocaine SelfAdministration in Rats: Opposite Effects of the Type II Glucocorticoid Receptor Agonist
 Dexamethasone. Journal of Pharmacology and Experimental Therapeutics 287, 72 (1998).
- 864 39 Evan, N. G. *et al.* Corticosterone Acts in the Nucleus Accumbens to Enhance Dopamine 865 Signaling and Potentiate Reinstatement of Cocaine Seeking. *The Journal of Neuroscience*
- 865 Signaling and Potentiate Reinstatement of Cocaine Seeking. *The Journal of Neuroscience* 33, 11800 (2013). <u>https://doi.org:10.1523/JNEUROSCI.1969-13.2013</u>
- 86740Filion, G. J. et al. A family of human zinc finger proteins that bind methylated DNA and repress
transcription. Mol Cell Biol 26, 169-181 (2006). https://doi.org:10.1128/mcb.26.1.169-181.2006

869 41 Guardia, C. M., De Pace, R., Mattera, R. & Bonifacino, J. S. Neuronal functions of adaptor 870 complexes involved in protein sorting. Curr Opin Neurobiol 51, 103-110 (2018). 871 https://doi.org:10.1016/j.conb.2018.02.021 872 42 Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and 873 functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51, 874 D638-d646 (2023). https://doi.org:10.1093/nar/gkac1000 875 43 Hardee, I. et al. Defective ciliogenesis in INPP5E-related Joubert syndrome. Am J Med Genet 876 877 A 173, 3231-3237 (2017). https://doi.org:10.1002/ajmg.a.38376 44 DeMars, K. M., Ross, M. R., Starr, A. & McIntyre, J. C. Neuronal primary cilia integrate 878 peripheral signals with metabolic drives. Front Physiol 14, 1150232 (2023). 879 https://doi.org:10.3389/fphys.2023.1150232 880 45 Garcia-Gonzalo, F. R. et al. Phosphoinositides Regulate Ciliary Protein Trafficking to Modulate 881 Hedgehog Signaling. Dev Cell 34, 400-409 (2015). 882 https://doi.org:10.1016/j.devcel.2015.08.001 883 Everett, T. et al. Cilia loss on distinct neuron populations differentially alters cocaine-induced 46 884 locomotion and reward. J Psychopharmacol 38, 200-212 (2024). 885 https://doi.org:10.1177/02698811231219058 886 47 Ramos, C. et al. Neuron-specific cilia loss differentially alters locomotor responses to 887 amphetamine in mice. J Neurosci Res 99, 827-842 (2021), https://doi.org:10.1002/inr.24755 888 48 Gao, P., Limpens, J. H. W., Spijker, S., Vanderschuren, L. J. M. J. & Voorn, P. Stable 889 immediate early gene expression patterns in medial prefrontal cortex and striatum after long-890 term cocaine self-administration. Addiction Biology 22, 354-368 (2017). 891 https://doi.org:https://doi.org/10.1111/adb.12330 892 49 Robinson, T. E., Gorny, G., Mitton, E. & Kolb, B. Cocaine self-administration alters the 893 morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. 894 Synapse 39, 257-266 (2001). https://doi.org:10.1002/1098-2396(20010301)39:3<257::Aid-895 syn1007>3.0.Co;2-1 896 50 Caffino, L., Messa, G. & Fumagalli, F. A single cocaine administration alters dendritic spine 897 morphology and impairs glutamate receptor synaptic retention in the medial prefrontal cortex 898 of adolescent rats. Neuropharmacology 140, 209-216 (2018). 899 https://doi.org:https://doi.org/10.1016/j.neuropharm.2018.08.006 900 51 Koob, G. F. & Volkow, N. D. Neurocircuitry of Addiction. Neuropsychopharmacology 35, 217-901 238 (2010). https://doi.org:10.1038/npp.2009.110 902 52 Zhou, Z., Yuan, Q., Mash, D. C. & Goldman, D. Substance-specific and shared transcription 903 and epigenetic changes in the human hippocampus chronically exposed to cocaine and 904 alcohol. Proceedings of the National Academy of Sciences 108, 6626-6631 (2011). 905 https://doi.org:10.1073/pnas.1018514108 906 53 Pati, S., Angel, P., Drake, R. R., Wagner, J. J. & Cummings, B. S. Lipidomic changes in the 907 rat hippocampus following cocaine conditioning, extinction, and reinstatement of drug-seeking. 908 Brain Behav 9, e01451 (2019). https://doi.org:10.1002/brb3.1451 909 54 Ersche, K. D., Stochl, J., Woodward, J. M. & Fletcher, P. C. The skinny on cocaine: insights 910 into eating behavior and body weight in cocaine-dependent men. Appetite 71, 75-80 (2013). 911 https://doi.org:10.1016/j.appet.2013.07.011 912 Martinez, L. A., Lees, M. E., Ruskin, D. N. & Masino, S. A. A ketogenic diet diminishes 55 913 behavioral responses to cocaine in young adult male and female rats. Neuropharmacology 914 149, 27-34 (2019). https://doi.org:10.1016/j.neuropharm.2019.02.001 915 56 Heinz, A. et al. Addiction Research Consortium: Losing and regaining control over drug intake 916 (ReCoDe)-From trajectories to mechanisms and interventions. Addict Biol 25, e12866 (2020). 917 https://doi.org:10.1111/adb.12866 918 57 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful 919 Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B 920 (Methodological) 57, 289-300 (1995). 921 58 Lehne, B. et al. A coherent approach for analysis of the Illumina HumanMethylation450 922 BeadChip improves data quality and performance in epigenome-wide association studies. 923 Genome Biol 16, 37 (2015). https://doi.org:10.1186/s13059-015-0600-x 924 Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture 59 925 distribution. BMC Bioinformatics 13, 86 (2012). https://doi.org:10.1186/1471-2105-13-86 926 Jaffe, A. E. & Kaminsky, Z. FlowSorted. Blood. 450k: Illumina HumanMethylation data on 60 927 sorted blood cell populations. R package version 1 (2017). 928 61 Dobin, A. et al. STAR: ultrafast universal RNA-seg aligner. Bioinformatics 29, 15-21 (2013). 929 https://doi.org:10.1093/bioinformatics/bts635

- 93062Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better931for alignment and quantification of RNA sequencing reads. Nucleic Acids Research 47, e47-932e47 (2019). https://doi.org:10.1093/nar/gkz114
- 93363Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for934934RNA-seq data with DESeq2. Genome Biology 15, 550 (2014). https://doi.org.10.1186/s13059-014-0550-8
- 93664Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat937Methods 12, 453-457 (2015). https://doi.org:10.1038/nmeth.3337
- 93865Yu, Q. & He, Z. Comprehensive investigation of temporal and autism-associated cell type939composition-dependent and independent gene expression changes in human brains. Scientific940Reports 7, 4121 (2017). https://doi.org/10.1038/s41598-017-04356-7
- 94166Kruschke, J. K. Bayesian estimation supersedes the t test. J Exp Psychol Gen 142, 573-603942(2013). https://doi.org/10.1037/a0029146
- 943 67 Shen L, S. I. GeneOverlap: Test and visualize gene overlaps. R package version 1.36.0. (2023).
- 94568Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing
biological themes among gene clusters. *Omics* **16**, 284-287 (2012).947https://doi.org:10.1089/omi.2011.0118
- 94869Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network949analysis. BMC Bioinformatics **9**, 559 (2008). https://doi.org:10.1186/1471-2105-9-559
- 95070Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular951interaction networks. Genome Res 13, 2498-2504 (2003). https://doi.org/10.1101/gr.1239303
- 95271Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: Network953Analysis and Visualization of Proteomics Data. J Proteome Res 18, 623-632 (2019).954https://doi.org:10.1021/acs.jproteome.8b00702
- 95572Friedman, M. J. et al. VA's National PTSD Brain Bank: a National Resource for Research.956Curr Psychiatry Rep 19, 73 (2017). https://doi.org/10.1007/s11920-017-0822-6
- 95773Girgenti, M. J. et al. Transcriptomic organization of the human brain in post-traumatic stress958disorder. Nat Neurosci 24, 24-33 (2021). https://doi.org:10.1038/s41593-020-00748-7
- 95974Cahill, K. M., Huo, Z., Tseng, G. C., Logan, R. W. & Seney, M. L. Improved identification of
concordant and discordant gene expression signatures using an updated rank-rank
hypergeometric overlap approach. Sci Rep 8, 9588 (2018). https://doi.org.10.1038/s41598-
- 963
 75
 Subramanian, A. *et al.* A Next Generation Connectivity Map: L1000 Platform and the First

 964
 1,000,000 Profiles. *Cell* **171**, 1437-1452.e1417 (2017).

 965
 https://doi.org:10.1016/j.cell.2017.10.049
- 96676Kurtenbach, S. & Harbour, J. W. SparK: A Publication-quality NGS Visualization Tool. *bioRxiv*,
845529 (2019). https://doi.org/10.1101/845529
- 96877An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74969(2012). https://doi.org:10.1038/nature11247
- 97078Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079971(2009). https://doi.org:10.1093/bioinformatics/btp352
- 97279Ramírez, F. et al. deepTools2: a next generation web server for deep-sequencing data973analysis. Nucleic Acids Research 44, W160-W165 (2016). https://doi.org.10.1093/nar/gkw257
- 97480de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set975analysis of GWAS data. PLoS Comput Biol 11, e1004219 (2015).976https://doi.org:10.1371/journal.pcbi.1004219
- Argelaguet, R. *et al.* Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. *Molecular Systems Biology* 14, e8124 (2018).
 https://doi.org/https://doi.org/10.15252/msb.20178124
- Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
 interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550
 (2005). <u>https://doi.org:10.1073/pnas.0506580102</u>